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Abstract 
We report a case of a primary pericardial
malignant  mesothelioma.  A  59-year-old  male
presented with episodic chest pain and dysp-
nea on exertion. Cardiac magnetic resonance
imaging revealed a large mass in the pericardi-
um  attached  to  the  right  ventricle.  Partial
resection of the mass was undertaken reveal-
ing  malignant  mesothelioma,  byphasic  type.
The  patient  was  treated  with  chemotherapy
intermittently over a period of 3 years, but his
disease continued to progress. The patient was
then treated with definitive radiation therapy
to 64 Gy to the primary tumor using a six field
3D conformal technique. The patient remains
free of progressive disease 86 months from the
time of diagnosis and 50 months from the com-
pletion of his radiotherapy.
Case Report
A  59-year-old  African  American  male  with
essentially no significant past medical history
except for hypertension and obesity presented
to the emergency room on April 27, 2003 with
a complaint of episodic chest pain and increas-
ing  dyspnea  on  exertion  over  the  previous
month. An EKG revealed sinus tachycardia but
was otherwise within normal limits. A chest x-
ray  was  performed  and  revealed  a  bottle-
shaped  heart  consistent  with  a  pericardial
effusion.  The  echocardiogram  subsequently
performed showed a right ventricular pericar-
dial  mass.  A  CT  of  the  patient’s  chest,
abdomen, and pelvis revealed a moderate peri-
cardial effusion and high attenuation focally in
the  anterior  pericardium  consistent  with  a
pericardial mass. The scan revealed an other-
wise normal abdomen and pelvis examination
with  no  evidence  of  metastatic  disease.
Subsequently  a  cardiac  magnetic  resonance
image (MRI) was performed revealing a mass
within  the  pericardial  space  measuring
7.7¥3.6 cm, adhering to the right ventricle epi-
cardium  without  myocardial  infiltration  and
compressing  the  right  ventricular  apex.  The
mass was not lipomatous and took up contrast
consistent with vascularity (Figure 1A). A mod-
erate pericardial effusion was also present.
Pathological findings
The patient was subsequently taken to the
operating room to create a pericardial window
to alleviate his pericardial effusion, as well as
a partial resection of his tumor. An aggregrate
of approximately 6.5¥6.5¥2.5 cm of tumor was
removed. However, a complete resection could
not be performed due to tumor adherence to
the right ventricular muscle. On gross review
of the pathology specimen, the interior of the
mass  appeared  necrotic  with  outer  tissue
showing  smooth,  glistening  serosal  surfaces
with  small  papillary  excrescences.  Pathology
demonstrated a biphasic (epithelial and spin-
dle cell) histology characteristic of mesothe-
lioma,  with  immunohistochemistry  showing
cytokeratin positivity in both cellular compo-
nents, and calretinin (a mesothelioma-specific
immunhistochemical  stain)  positivity  in  the
epithelioid  cells.  The  final  pathology  of  the
tumor specimen was reported as a malignant
mesothelioma: biphasic type (Figure 2). 
Therapeutic intervention
The patient was treated initially with eight
cycles  of  gemcitabine  and  cisplatin,  with  a
good partial response to treatment. This treat-
ment ended in March 2004. The patient was
subsequently  followed  with  serial  imaging,
which  showed  stable  disease  until  January
2005, when an increase in size of the patient’s
pericardial mass was appreciated. An addition-
al  six  cycles  of  chemotherapy  was  adminis-
tered with gemcitabine and carboplatin. The
last cycle was given in July 2005. No further
disease progression or regression was appreci-
ated until November of 2005, when once again,
the patient was noted to have disease progres-
sion. He subsequently received two cycles of
permextred,  but  a  MRI  in  January  2006
revealed  that  the  anterior  pericardial  mass
located  in  the  interventricular  groove  had
increased in size to 7.4¥4.8¥4.2 cm (previous
3.3¥4.6¥5.4  cm).  There  was  continued  com-
pression  of  the  right  ventricle,  slightly
increased from prior examination. The right
atrium was mildly enlarged, which was new
from  prior  examination  (Figure  1B).  The
patient was also beginning to once again expe-
rience increasing dyspnea on exertion and was
then referred to Radiation Oncology and treat-
ed on an Elekta SL-18 linear accelerator from
March 2, 2006 until April 18, 2006. He was pre-
scribed a total dose of 64 Gray in 32 fractions
yielding  a  daily  dose  of  2  Gray  per  fraction
delivered to the 100% isodose line using 6 MV
photons. He was treated using a 6-field non-
coplanar 3D conformal technique with a right
anterior oblique field measuring 12.2¥9.6 cm,
a right superior anterior oblique field measur-
ing  10.5¥12.3  cm,  a  left  inferior  anterior
oblique field measuring 12.1¥10.7 cm, a right
inferior  anterior  oblique  field  measuring
14.2¥10.7 cm, a left superior anterior oblique
field measuring 13.9¥10.6 cm and a left lateral
field  measuring  13.5¥10.8  cm.  Sixty-degree
wedges were used on all fields to improve dose
homogeneity  and  blocks  were  used  to  spare
normal tissues (Figure 3). Overall, the patient
tolerated his radiation treatments quite well
and noted improvement in his dyspnea at the
end of treatment. 
Radiographic response assessment
At the completion of his radiation therapy a
cardiac MRI was performed, which again identi-
fied a solid enhancing pericardial mass along
the anterior/apical region of the right ventricle.
The mass had decreased in size, now measur-
ing 2.1¥3.5¥5.2 cm. Volumetric measurements
of the mass demonstrated the mass to be 1/5 the
volume compared to pretreatment examination
Rare Tumors 2010; volume 2:e51
Correspondence:  Paul  W.  Read,  Department  of
Radiation Oncology, University of Virginia, P.O.
Box 800383, Charlottesville, VA 22908, USA. 
E-mail: pwr3u@virginia.edu
Key words: pericardial mesothelioma, radiation.
Acknowledgements:  the  authors  would  like  to
thank Constance Geesey, radiation dosimetrist,
in the Department of Radiation Oncology at the
University of Virginia, for her help with data col-
lection.
Contributions:  KR,  review  of  the  patient  case
report, literature review and writing of the manu-
script;  MR,  radiologic  image  and  manuscript
review; CM, pathological review of the case and
contribution to the pathology discussion; WG, pri-
mary medical oncologist, manuscript review; PR,
manuscript review.
Conflict of interest: the authors report no conflict
of interest.
Received for publication: 13 July 2010. 
Accepted for publication: 26 July 2010. 
This work is licensed under a Creative Commons
Attribution 3.0 License (by-nc 3.0).
©Copyright K.A. Reardon et al., 2010
Licensee PAGEPress, Italy
Rare Tumors 2010; 2:e51
doi:10.4081/rt.2010.e51[Rare Tumors 2010; 2:e51] [page 147]
(Figure 1C). The patient was subsequently fol-
lowed with serial imaging after the completion
of his radiation therapy. At 40 months post-radi-
ation  treatment,  imaging  revealed  a  small
amount of anterior pericardial thickening with
a  maximal  thickness  of  8  mm,  which  had
remained unchanged since December 2007. No
discrete  mass  lesion  was  identified,  and  the
remainder of the pericardium was unremark-
able. Given the stability of the thickening, this
was felt to most likely represent post-radiation
changes  (Figure  1D).  The  patient  is  now  86
months from diagnosis and 50 months from the
completion of his radiation therapy with no evi-
dence of progressive disease. Additionally, the
patient has minimal symptoms with no baseline
shortness of breath and stable dyspnea on exer-
tion since the completion of his radiation ther-
apy. He has had no late lung radiation toxicity,
and his most recent cardiac ejection fraction
was  found  to  be  48%  (normal  56-78%)  in
February  2010,  which  was  only  slightly
decreased from prior to radiation, where it was
found to be between 50-55% in February 2006. 
Discussion
The most common tumor arising from the
pericardium is a secondary tumor with metas-
tases  most  frequently  arising  from  lung,
breast, melanoma, and lymphoma.
1 In a study
of 2649 autopsies performed in patients with
malignant tumors, there were 407 cases of sec-
ondary involvement of the heart and/or peri-
cardium but only 1 case of a primary tumor
(malignant mesothelioma).
2 Primary pericar-
dial  tumors  are  rare  entities,  and  include
benign  (teratomas,  fibromas,  angiomas  and
lipomas)  and  malignant  (mesothelioma  and
sarcoma) tumors.
3
Although primary pericardial mesothelioma
is  infrequent,  it  is  the  third  most  common
tumor of the heart/pericardium after angiosar-
coma  (33%)  and  rhabdomyosarcoma  (20%).
4
In a study of about 500,000 autopsies, its inci-
dence was <0.0022%
5 however, it accounts for
approximately 2-3% of all cardiac and pericar-
dial  primary  tumors.
4,6 Mesothelioma  arises
from the serous epithelial cells of the mesothe-
lium. The most common sites for this malig-
nancy  include  the  pleura  (60-70%)  and  the
peritoneum  (30-35%).  Primary  pericardial
mesothelioma accounts for only about 1% of all
mesotheliomas.
4-6 Pericardial  mesothelioma
can present as a localized lesion or a diffuse
infiltration of the pericardium. Four histologi-
cal  types  have  been  described  including
epitheliod,  sarcomatoid,  desmoplastic  and
biphasic.
7 Pleural  and  peritoneal  mesothe-
lioma development has been correlated with
exposure  to  asbestos;  however,  the  role  of
asbestos  in  pericardial  mesothelioma  is
unclear.
6-8 A rare association with pericardial
mesothelioma  and  tuberculosis  has  been
reported.
9
Symptoms arising from primary pericardial
mesothelioma usually result from constriction
of  the  heart  or  compression  of  surrounding
structures, ranging from dyspnea, cough, dys-
phagia and chest pain.
8 The onset of symptoms
is usually insidious. Constrictive pericarditis,
pericardial  effusion,  cardiac  tamponade  and
heart failure can all be clinical manifestations
of pericardial mesothelioma. Compression of
coronary arteries and local spread of the dis-
ease to surrounding large vessels can result in
additional  symptoms.
3 Additionally,  distant
metastases, myocardial infarction secondary to
conduction  blockade,  as  well  as  tumor
embolism  causing  neurological  deficits  have
been reported.
10,11
Diagnosis of the disease can be challenging,
and  in  only  10-20%  of  cases  a  diagnosis  is
made prior to the patient’s death.
6 The initial
test  usually  consists  of  an  echocardiogram.
Imaging such as MRI and CT can be helpful in
identifying the extent of disease and infiltra-
tion into adjacent structures; an ultrasound or
CT guided biopsy of the pericardium can also
be performed. Moreover, cytological examina-
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Figure 1. Cardiac magnetic resonance imaging. (A) At diagnosis. (B) Pre-radiation. (C)
Post-radiation. (D) 40 months post-radiation.
Figure 2. Tumor histology. (A) The tumor was composed of sheets of large pleomorphic
epitheliod cells with abundant pale cytoplasm and well demarcated cell borders. The
tumor demonstrated geographic areas of necrosis (*). Hematoxylin and eosin stain, orig-
inal magnification x40 (inset x400). (B) In an immunohistochemical stain for calretinin,
a marker of mesothelial differentiation, the tumor cells showed strong and diffuse brown
staining. Hematoxylin counterstain, original magnification x200.[page 148] [Rare Tumors 2010; 2:e51]
tion, immunohistochemistry, and high pericar-
dial hyaluronic acid content of the pericardial
aspirate can be diagnostic; however, pericar-
dial fluid in pericardial mesothelioma can be
difficult to aspirate.
3 Mesothelioma cells stain
positive  for  cytokeratin,  vimentin,  epithelial
membrane antigen and calretinin, and nega-
tive for CEA, CD15 and S-100.
12,13 The tumor
can readily metastasize and involve regional
lymph nodes, lungs and kidneys, doing so in
approximately 25-45% of patients.
14
In regards to treatment, surgical resection
can be curative in localized cases. Reduction
of the mass has been achieved with cyclical
combination chemotherapy with doxorubicin,
vincristine, and cyclophosphamide as well as
with radiotherapy.
3,6 However, despite the best
efforts,  no  significant  difference  has  been
achieved  in  regards  to  prognosis,  and  the
median  survival  time  is  approximately  6
months from diagnosis.
7,15 Ongoing research
for this disease includes such devices as intra-
cavitary chemotherapy and irradiation, photo-
dynamic therapy, inhibition of growth factors,
and vaccines.
16
Conclusions
Primary  pericardial  mesotheliomas  are
rare  tumors.  We  report  a  case  of  a  patient
with primary pericardial malignant mesothe-
lioma with a complete clinical response and
local control at 50 months following high dose
radiation.  Modest  benefits  are  generally
reported  with  chemotherapy  and  radiation,
and  median  life  expectancy  is  very  low.
Despite these facts, we recommend consider-
ation of curative high dose radiation as a rea-
sonable  treatment  option  for  patients  with
unresectable or recurrent primary pericardial
mesotheliomas.
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